Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 5/20 | 0.68 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.68 |
| ▸ | MALT1 | Q9UDY8 | 7/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3355870 | 0.89 | PTGS2 (0.55) | PTGS2PTGS1MALT1 | |
| SCHEMBL6132316 | 0.87 | PTGS2 (0.68) | PTGS2PTGS1MALT1L3MBTL1LMNA | |
| SCHEMBL6132341 | 0.86 | PTGS2 (0.67) | PTGS2PTGS1MALT1L3MBTL1LMNA | |
| SCHEMBL4026247 | 0.84 | PTGS1 (0.76) | PTGS2PTGS1MALT1L3MBTL1LMNA | |
| SCHEMBL4031131 | 0.83 | PTGS2 (0.81) | PTGS2PTGS1MALT1L3MBTL1LMNA | |
| SCHEMBL1193845 | 0.82 | PTGS2 (1.00) | PTGS2PTGS1MALT1L3MBTL1LMNA | |
| SCHEMBL4032188 | 0.82 | PTGS1 (0.72) | PTGS2PTGS1MALT1L3MBTL1 | |
| SCHEMBL10933434 | 0.81 | SMN1; SMN2 (0.46) | PTGS2PTGS1MALT1MAOAMAOB | |
| SCHEMBL6132289 | 0.80 | PTGS2 (1.00) | PTGS2PTGS1MALT1L3MBTL1 | |
| SCHEMBL3355058 | 0.78 | PTGS2 (0.55) | PTGS2PTGS1MALT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030191155-A1 | Triazole derivatives | ASTELLAS PHARMA INC. (JP) | 2003-10-09 | — | — | US | claimed |
| US-20130137739-A1 | SOLID DISPERSION COMPRISING TRIAZOLE COMPOUND | ASTELLAS PHARMA, INC. | 2013-05-30 | — | — | US | disclosed |
| EP-2581084-A1 | SOLID DISPERSION COMPRISING TRIAZOLE COMPOUND | Astellas Pharma Inc. (JP) | 2013-04-17 | — | — | EP | disclosed |
| US-6927230-B2 | Triazole derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-08-09 | — | — | US | disclosed |
| US-20030191155-A1 | Triazole derivatives | ASTELLAS PHARMA INC. (JP) | 2003-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191155-A1 | Triazole derivatives | CBR1, CBR3, CYP1B1 | PTGS2 2680/4885PTGS1 1504/4885MALT1 71/4885 |
| US-20130137739-A1 | SOLID DISPERSION COMPRISING TRIAZOLE COMPOUND | CYP3A4, CYP3A43, CYP3A7 | PTGS2 3116/4885PTGS1 2201/4885MALT1 840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.